annual EBITDA:
$29.39M+$121.47M(+131.92%)Summary
- As of today (May 26, 2025), FOLD annual EBITDA is $29.39 million, with the most recent change of +$121.47 million (+131.92%) on December 31, 2024.
- During the last 3 years, FOLD annual EBITDA has risen by +$232.26 million (+114.49%).
- FOLD annual EBITDA is now at all-time high.
Performance
FOLD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$4.75M-$26.69M(-121.67%)Summary
- As of today (May 26, 2025), FOLD quarterly EBITDA is -$4.75 million, with the most recent change of -$26.69 million (-121.67%) on March 31, 2025.
- Over the past year, FOLD quarterly EBITDA has increased by +$24.24 million (+83.61%).
- FOLD quarterly EBITDA is now -114.13% below its all-time high of $33.63 million, reached on December 31, 2009.
Performance
FOLD quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$53.63M+$24.24M(+82.48%)Summary
- As of today (May 26, 2025), FOLD TTM EBITDA is $53.63 million, with the most recent change of +$24.24 million (+82.48%) on March 31, 2025.
- Over the past year, FOLD TTM EBITDA has increased by +$134.58 million (+166.25%).
- FOLD TTM EBITDA is now at all-time high.
Performance
FOLD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FOLD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +131.9% | +83.6% | +166.3% |
| 3 y3 years | +114.5% | +93.4% | +124.3% |
| 5 y5 years | +108.8% | +94.3% | +117.7% |
FOLD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +114.5% | -121.7% | +93.4% | at high | +122.8% |
| 5 y | 5-year | at high | +108.8% | -121.7% | +94.3% | at high | +117.7% |
| alltime | all time | at high | +106.9% | -114.1% | +98.3% | at high | +112.3% |
FOLD EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$4.75M(-121.7%) | $53.63M(+82.5%) |
| Dec 2024 | $29.39M(-131.9%) | $21.93M(+1.3%) | $29.39M(-419.6%) |
| Sep 2024 | - | $21.65M(+46.2%) | -$9.20M(-77.2%) |
| Jun 2024 | - | $14.80M(-151.1%) | -$40.33M(-50.2%) |
| Mar 2024 | - | -$28.99M(+74.1%) | -$80.95M(-12.1%) |
| Dec 2023 | -$92.08M(-53.9%) | -$16.65M(+75.4%) | -$92.08M(-30.8%) |
| Sep 2023 | - | -$9.49M(-63.2%) | -$133.10M(-6.2%) |
| Jun 2023 | - | -$25.82M(-35.6%) | -$141.97M(-15.4%) |
| Mar 2023 | - | -$40.12M(-30.4%) | -$167.80M(-15.9%) |
| Dec 2022 | -$199.58M(-1.6%) | -$57.67M(+214.2%) | -$199.58M(-6.1%) |
| Sep 2022 | - | -$18.36M(-64.5%) | -$212.52M(-9.5%) |
| Jun 2022 | - | -$51.66M(-28.2%) | -$234.95M(+6.7%) |
| Mar 2022 | - | -$71.89M(+1.8%) | -$220.28M(+8.6%) |
| Dec 2021 | -$202.87M(-16.5%) | -$70.61M(+73.1%) | -$202.87M(+4.0%) |
| Sep 2021 | - | -$40.79M(+10.3%) | -$195.03M(-6.3%) |
| Jun 2021 | - | -$36.98M(-32.1%) | -$208.24M(-2.9%) |
| Mar 2021 | - | -$54.49M(-13.2%) | -$214.38M(-11.8%) |
| Dec 2020 | -$242.98M(-26.9%) | -$62.77M(+16.2%) | -$242.98M(-8.2%) |
| Sep 2020 | - | -$54.00M(+25.3%) | -$264.82M(-1.1%) |
| Jun 2020 | - | -$43.12M(-48.1%) | -$267.73M(-11.5%) |
| Mar 2020 | - | -$83.09M(-1.8%) | -$302.67M(-8.9%) |
| Dec 2019 | -$332.26M(+3.0%) | -$84.60M(+48.6%) | -$332.26M(+5.5%) |
| Sep 2019 | - | -$56.92M(-27.1%) | -$314.89M(-23.5%) |
| Jun 2019 | - | -$78.06M(-30.7%) | -$411.40M(+5.7%) |
| Mar 2019 | - | -$112.69M(+67.6%) | -$389.30M(+20.7%) |
| Dec 2018 | -$322.47M(-24.7%) | -$67.23M(-56.2%) | -$322.47M(+0.9%) |
| Sep 2018 | - | -$153.43M(+174.2%) | -$319.46M(-26.9%) |
| Jun 2018 | - | -$55.96M(+22.0%) | -$437.18M(+3.0%) |
| Mar 2018 | - | -$45.85M(-28.6%) | -$424.31M(-0.9%) |
| Dec 2017 | -$428.29M(+119.5%) | -$64.22M(-76.3%) | -$428.29M(+1.3%) |
| Sep 2017 | - | -$271.15M(+529.2%) | -$422.96M(+115.5%) |
| Jun 2017 | - | -$43.09M(-13.5%) | -$196.31M(-3.2%) |
| Mar 2017 | - | -$49.82M(-15.4%) | -$202.89M(+4.0%) |
| Dec 2016 | -$195.14M(+51.6%) | -$58.89M(+32.4%) | -$195.14M(+9.8%) |
| Sep 2016 | - | -$44.49M(-10.4%) | -$177.72M(+4.2%) |
| Jun 2016 | - | -$49.68M(+18.1%) | -$170.61M(+15.8%) |
| Mar 2016 | - | -$42.07M(+1.5%) | -$147.37M(+14.5%) |
| Dec 2015 | -$128.71M | -$41.47M(+10.9%) | -$128.71M(+18.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$37.39M(+41.4%) | -$108.83M(+23.9%) |
| Jun 2015 | - | -$26.44M(+13.0%) | -$87.84M(+16.7%) |
| Mar 2015 | - | -$23.41M(+8.4%) | -$75.24M(+12.3%) |
| Dec 2014 | -$67.01M(+9.2%) | -$21.59M(+31.7%) | -$67.01M(+10.3%) |
| Sep 2014 | - | -$16.40M(+18.4%) | -$60.74M(+3.8%) |
| Jun 2014 | - | -$13.84M(-8.8%) | -$58.50M(-1.8%) |
| Mar 2014 | - | -$15.18M(-1.0%) | -$59.55M(-3.0%) |
| Dec 2013 | -$61.38M(+22.2%) | -$15.33M(+8.3%) | -$61.38M(+4.2%) |
| Sep 2013 | - | -$14.15M(-4.9%) | -$58.88M(-2.8%) |
| Jun 2013 | - | -$14.89M(-12.5%) | -$60.58M(+11.0%) |
| Mar 2013 | - | -$17.01M(+32.6%) | -$54.57M(+8.6%) |
| Dec 2012 | -$50.24M(+8.5%) | -$12.83M(-19.1%) | -$50.24M(+1.8%) |
| Sep 2012 | - | -$15.85M(+78.4%) | -$49.33M(+15.2%) |
| Jun 2012 | - | -$8.89M(-29.9%) | -$42.83M(-7.1%) |
| Mar 2012 | - | -$12.67M(+6.3%) | -$46.12M(-0.4%) |
| Dec 2011 | -$46.31M(-13.9%) | -$11.92M(+27.5%) | -$46.31M(-7.5%) |
| Sep 2011 | - | -$9.35M(-23.2%) | -$50.07M(-9.8%) |
| Jun 2011 | - | -$12.17M(-5.4%) | -$55.51M(+2.7%) |
| Mar 2011 | - | -$12.86M(-18.0%) | -$54.06M(+0.6%) |
| Dec 2010 | -$53.76M(+1193.2%) | -$15.69M(+6.2%) | -$53.76M(+1110.4%) |
| Sep 2010 | - | -$14.78M(+37.7%) | -$4.44M(+81.6%) |
| Jun 2010 | - | -$10.73M(-14.5%) | -$2.44M(-48.8%) |
| Mar 2010 | - | -$12.56M(-137.3%) | -$4.78M(+14.9%) |
| Dec 2009 | -$4.16M(-89.0%) | $33.63M(-363.0%) | -$4.16M(-91.2%) |
| Sep 2009 | - | -$12.78M(-2.1%) | -$47.39M(+8.9%) |
| Jun 2009 | - | -$13.06M(+9.4%) | -$43.52M(+7.2%) |
| Mar 2009 | - | -$11.94M(+24.3%) | -$40.62M(+7.9%) |
| Dec 2008 | -$37.64M(-15.5%) | -$9.60M(+7.7%) | -$37.64M(-8.7%) |
| Sep 2008 | - | -$8.92M(-12.2%) | -$41.21M(-5.9%) |
| Jun 2008 | - | -$10.16M(+13.3%) | -$43.79M(+0.4%) |
| Mar 2008 | - | -$8.97M(-31.9%) | -$43.60M(-2.2%) |
| Dec 2007 | -$44.57M(-2.9%) | -$13.17M(+14.6%) | -$44.57M(+41.9%) |
| Sep 2007 | - | -$11.49M(+15.2%) | -$31.40M(+57.7%) |
| Jun 2007 | - | -$9.97M(+0.4%) | -$19.91M(+100.4%) |
| Mar 2007 | - | -$9.94M | -$9.94M |
| Dec 2006 | -$45.91M(+127.7%) | - | - |
| Dec 2005 | -$20.16M(+211.8%) | - | - |
| Dec 2003 | -$6.47M | - | - |
FAQ
- What is Amicus Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Amicus Therapeutics?
- What is Amicus Therapeutics annual EBITDA year-on-year change?
- What is Amicus Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly EBITDA year-on-year change?
- What is Amicus Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Amicus Therapeutics?
- What is Amicus Therapeutics TTM EBITDA year-on-year change?
What is Amicus Therapeutics annual EBITDA?
The current annual EBITDA of FOLD is $29.39M
What is the all time high annual EBITDA for Amicus Therapeutics?
Amicus Therapeutics all-time high annual EBITDA is $29.39M
What is Amicus Therapeutics annual EBITDA year-on-year change?
Over the past year, FOLD annual EBITDA has changed by +$121.47M (+131.92%)
What is Amicus Therapeutics quarterly EBITDA?
The current quarterly EBITDA of FOLD is -$4.75M
What is the all time high quarterly EBITDA for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly EBITDA is $33.63M
What is Amicus Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FOLD quarterly EBITDA has changed by +$24.24M (+83.61%)
What is Amicus Therapeutics TTM EBITDA?
The current TTM EBITDA of FOLD is $53.63M
What is the all time high TTM EBITDA for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM EBITDA is $53.63M
What is Amicus Therapeutics TTM EBITDA year-on-year change?
Over the past year, FOLD TTM EBITDA has changed by +$134.58M (+166.25%)